A Case of New-onset Psoriasis During Docetaxel Treatment

다국어 초록 (Multilingual Abstract)

Docetaxel is one of the most widely used cytotoxic chemotherapeutic agents, indicated for the treatment of various types of cancer. Dermatological adverse events such as hand-foot syndrome, alopecia, nail changes, and mucositis are frequently reported. However, psoriasis induced by docetaxel is very rare. Herein, we report the case of a 70-year-old patient who developed scaly erythematous plaques after one month of docetaxel chemotherapy for the treatment of stage IV lung adenocarcinoma. Histopathologic findings were consistent with psoriasis, and he was finally diagnosed with docetaxel-induced psoriasis. Skin lesions improved after docetaxel discontinuation and application of fixed combination of topical calcipotriol and betamethasone.

참고문헌 (Reference)

1 Gelmon K, "The taxoids : paclitaxel and docetaxel" 344 : 1267-1272, 1994

2 Poikonen P, "Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel" 43 : 190-195, 2004

3 Li JY, "Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer" 286170-, 2014

4 Nussbaum L, "Role of regulatory T cells in psoriasis pathogenesis and treatment" 184 : 14-24, 2021

5 Jones SE, "Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer" 23 : 5542-5551, 2005

6 Kurian M, "Psoriasis Flare-Up in a Patient Treated With Docetaxel for Metastatic Prostate Cancer" 15 : e34726-, 2023

7 Rowinsky EK, "Paclitaxel (taxol)" 332 : 1004-1014, 1995

8 Markman M, "Managing taxane toxicities" 11 : 144-147, 2003

9 Balak DM, "Drug-induced psoriasis : clinical perspectives" 7 : 87-94, 2017

10 Poi MJ, "Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage : a case series and literature review" 21 : 2679-2686, 2013

11 Morimoto H, "Docetaxel-induced psoriasis with positive scratch patch test" 50 : e381-e383, 2023

12 Allende I, "Docetaxel-induced psoriasis" 100 : 629-630, 2009

13 양승걸 ; 김보리 ; 최종원 ; 윤상웅, "Docetaxel-Aggravated Psoriasis" 대한피부과학회 31 (31): 240-241, 2019

14 Imran M, "Docetaxel : An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer" 60 : 101959-, 2020

15 Cortes JE, "Docetaxel" 13 : 2643-2655, 1995

16 Watabe D, "Development of psoriasis during docetaxel therapy in a patient with non-small-cell lung cancer" 47 : e427-e428, 2020

17 Sibaud V, "Dermatological adverse events with taxane chemotherapy" 26 : 427-443, 2016

18 Payne AS, "Dermatologic toxicity of chemotherapeutic agents" 33 : 86-97, 2006

19 Kodumudi KN, "A novel chemoimmunomodulating property of docetaxel : suppression of myeloid-derived suppressor cells in tumor bearers" 16 : 4583-4594, 2010

20 Naranjo CA, "A method for estimating the probability of adverse drug reactions" 30 : 239-245, 1981